Exscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, is delighted to announce success at the 2017 Courier Awards, held in Dundee and organised by D.C. Thomson, a leading British publishing house.
The award, for Science and Technology Business of the year, was presented to members of the Dundee team on Saturday 28th October at the annual awards. Judges for this year represented all the award categories and included the Chairman of Clydesdale Bank and the Director of the new V&A Museum of Design. At the same ceremony, Exscientia was also highly commended in the Design and Innovation category.
The award for Science and Technology recognises Exscientia's substantial growth over the past year through its application of AI and big data to accelerate drug discovery.
Exscientia's success is highlighted by collaborations with GSK and Sanofi as well as a recent minority investment from Evotec, representing further endorsement of Exscientia and validation of its approach.
Through these collaborations, the company is developing single-target small molecules as well as compounds with more challenging target product profiles, through a novel bispecific small molecule strategy (compounds with dual pharmacology in an integrated pharmacophore) and phenotypic-driven drug design.